Cabazitaxel: clinical trials recruiting now
8
Recruiting trials
8
Conditions studied
43
US states with sites
32
Countries
FDA drug label
- FDA-approved
- Yes. Cabazitaxel appears in the FDA drug-label database. Marketed as Jevtana.
- Boxed warning
- The FDA label for Cabazitaxel carries a boxed warning (the FDA's most serious warning). See the full label for details.
FDA-approved use
JEVTANA ® is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. JEVTANA is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. ( 1 )
Phase breakdown
Phase 1 3
Phase 2 4
Phase 3 3
Conditions being studied
Recruiting trials involving Cabazitaxel
- A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
- A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)
- Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
- Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
- Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
Common questions
Is Cabazitaxel FDA-approved?
Yes, marketed as Jevtana. Its FDA label carries a boxed warning.
How many recruiting trials involve Cabazitaxel?
8 recruiting trials across 8 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.